Financial Performance - The company expects a net loss of between 83 million and 98 million RMB for the fiscal year 2024, compared to a loss of 8.93 million RMB in the same period last year[2] - The expected net loss after deducting non-recurring gains and losses is between 114.95 million and 129.95 million RMB, compared to a loss of 59.93 million RMB in the previous year[2] - The decline in sales volume and prices of certain products has led to a decrease in operating revenue[4] - Non-recurring gains and losses are expected to impact net profit by approximately 31.95 million RMB[4] R&D and Investment - The company has increased R&D investment, which has impacted operating profit[4] - The company anticipates recognizing an investment loss of about 20.5 million RMB from certain joint ventures due to increased R&D expenses and fair value changes[4] Asset Impairment - An impairment of intangible assets is estimated at approximately 26 million RMB[4] Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed figures to be disclosed in the 2024 annual report[5]
莱美药业(300006) - 2024 Q4 - 年度业绩预告